CagriSema: Weight Loss in Overweight or Obese Adults
This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults who are overweight or obese. The study randomized over 3400 participants into groups receiving the combination therapy, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle interventions. Results demonstrated significant and clinically relevant body-weight […]
Dual-target weight loss drug controls blood sugar and appetite but causes gastrointestinal side effects in early trials
A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and appetite, was reported to reduce body weight by up to 24.3% when injected over 36 weeks, and 13.1% when taken orally over […]
Diabetes-Related Healthcare Costs Have Plateaued, Marking a Rare Opportunity for Employers, Nomi Health Report Finds
Image Credit: Nomi Health What You Should Know: – After decades of relentless increases, diabetes-related healthcare costs have finally plateaued, according to a new analysis by Nomi Health. The key finding from the company’s latest “Trends in Spend” report marks a rare moment of opportunity for self-funded employers to re-evaluate how they manage one of […]
GLP-1 Patients Missed Over $10M in Potential Savings in a Single Quarter, Report Finds
What You Should Know: – A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications. […]
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, giving momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide.
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA’s recent mandate. Hims pushed back against the accusation.
Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing
(MedPage Today) — CHICAGO — An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed. In the obesity…
STAT+: Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
CHICAGO — Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a mid-stage trial, results that support the company’s decision to use a slower dosing schedule to make the drug more tolerable in further testing. In the Phase 2 study, patients with obesity taking the […]
Food structure shown to play key role in which gut hormones are released
A new study from Imperial has shown that the physical structure of food influences the hormones released as part of digestion. These hormones include glucagon-like peptide-1 (GLP-1), GIP and PYY, as well as other post-meal responses like blood sugar, insulin and satiety hormones.
Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated – Expect Volatility
Post Content